CMMB — Chemomab Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Chemomab Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.5 | -27.6 | -24.2 | -13.9 | -8.99 |
| Depreciation | |||||
| Non-Cash Items | 2.23 | 4.12 | 0.754 | 0.668 | 0.352 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.16 | 3.1 | -0.211 | -2.16 | -2.56 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -12.4 | -20.4 | -23.6 | -15.4 | -11.1 |
| Capital Expenditures | -0.239 | -0.068 | -0.003 | 0 | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -44.9 | 19.6 | 15.9 | 2.3 | 5.39 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -45.2 | 19.5 | 15.9 | 2.3 | 5.39 |
| Financing Cash Flow Items | 2.43 | -1.22 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 61.1 | -0.808 | 3.5 | 9.87 | 7.16 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.51 | -1.65 | -4.23 | -3.22 | 1.42 |